Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 86.12B |
| Revenue (ttm) | 40.94B |
| Net Income (ttm) | 5.15B |
| Shares Out | n/a |
| EPS (ttm) | 2.53 |
| PE Ratio | 16.73 |
| Forward PE | 7.75 |
| Dividend | 2.22 (5.26%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 495 |
| Average Volume | 885 |
| Open | 42.12 |
| Previous Close | 42.26 |
| Day's Range | 42.00 - 42.50 |
| 52-Week Range | 36.65 - 58.50 |
| Beta | n/a |
| RSI | 57.64 |
| Earnings Date | Feb 5, 2026 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol Myers Squibb Unveils Positive Trial Data In Hematology Pipeline
(RTTNews) - Drug maker Bristol Myers Squibb Co. (BMY) announced Monday positive and promising data from the trials in Hematology pipeline, comprising Iberdomide, Golcadomide, BCL6 Degrader, as well as...
Bristol Myers (BMY) Showcases Breakthroughs in Hematology at ASH Meeting
Bristol Myers (BMY) Showcases Breakthroughs in Hematology at ASH Meeting
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the...
Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend?
The pharma stock yields more than 4x the S&P 500 average.
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
Bristol-Myers (BMY) Earnings Call Transcript
Bristol-Myers (BMY) Earnings Call Transcript
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
Bristol Myers Squibb Gets European Commission Approval To Expand Use Of Breyanzi In MCL
(RTTNews) - Bristol Myers Squibb (BMY), on Tuesday, announced that it has received approval from the European Commission to expand the use of its CAR T cell therapy Breyanzi for relapsed or refractory...
Bristol Myers Squibb (BMY) Gains EU Approval for Breyanzi in Mantle Cell Lymphoma
Bristol Myers Squibb (BMY) Gains EU Approval for Breyanzi in Mantle Cell Lymphoma
Bristol Myers (BMY) Gains EU Approval for Key Cancer Therapy
Bristol Myers (BMY) Gains EU Approval for Key Cancer Therapy
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian. • BMY shares are climbing. Find out why her...
Bristol Myers (BMY) Sees Stock Surge on Positive Drug Trial News
Bristol Myers (BMY) Sees Stock Surge on Positive Drug Trial News
Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer
Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.
Validea Detailed Fundamental Analysis - BMY
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...
BMY Quantitative Stock Analysis
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug
Texas Attorney General Ken Paxton escalated his campaign against major drugmakers this week, filing a new lawsuit accusing Sanofi SA (NASDAQ: SNY) and Bristol-Myers Squibb Co (NYSE: BMY) of conceali...
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Bristol-Myers Squibb (BMY) Faces Legal Action Over Plavix Effectiveness Claims
Bristol-Myers Squibb (BMY) Faces Legal Action Over Plavix Effectiveness Claims
Pharma giant gave Irish employee three months to come up with €20,800 to cover alleged ‘overpayment’, WRC hears
Employee challenging legality of Bristol Myers Squibb decision to deduct her salary by €870 a month over two years
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Bristol-Myers Squibb (BMY) Announces Early Results and Amendments to Cash Tender Offers
Bristol-Myers Squibb (BMY) Announces Early Results and Amendments to Cash Tender Offers
Why Bristol-Myers Squibb Remains Undervalued In 2025
Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the early participation results, as of 5:00 p.m. (New York City time) on November 17, 2025, (the “Early Tender Deadli...